UGM & Conference in Europe

In silico molecular risk profiling of biopharmaceuticals during early stage drug discovery

Alan Lewis
Scientific Leader and GSK Fellow, GlaxoSmithKline
(THURSDAY, May 18 - Scientific Presentations, 17:00-17:30)

The identification of a biopharmaceutical candidate molecule is often the product of a multi-round selection process based on both biological activity and developability. Whilst biological activity can be understood experimentally in a high-throughput manner, the methods to evaluate potential developmental risks tend to be more low-throughput. Molecules are therefore risk profiled using in silico methods, helping to prioritise molecules for selection and aid interpretation of subsequent experimental data. This presentation will give an outline of the in silico methods employed, and the incorporation of CCG MOE in this process.